Fig. 2From: Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trialCost-effectiveness acceptability curves for all analysesBack to article page